220 related articles for article (PubMed ID: 31735504)
21. Analysis of the vaccine-induced influenza B virus hemagglutinin-specific antibody dependent cellular cytotoxicity response.
de Vries RD; Nieuwkoop NJ; Krammer F; Hu B; Rimmelzwaan GF
Virus Res; 2020 Feb; 277():197839. PubMed ID: 31837382
[TBL] [Abstract][Full Text] [Related]
22. Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages.
Corbett KS; Moin SM; Yassine HM; Cagigi A; Kanekiyo M; Boyoglu-Barnum S; Myers SI; Tsybovsky Y; Wheatley AK; Schramm CA; Gillespie RA; Shi W; Wang L; Zhang Y; Andrews SF; Joyce MG; Crank MC; Douek DC; McDermott AB; Mascola JR; Graham BS; Boyington JC
mBio; 2019 Feb; 10(1):. PubMed ID: 30808695
[TBL] [Abstract][Full Text] [Related]
23. Identification of dominant antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin antigen of pandemic H1N1 influenza virus.
Srivastava V; Yang Z; Hung IF; Xu J; Zheng B; Zhang MY
J Virol; 2013 May; 87(10):5831-40. PubMed ID: 23487456
[TBL] [Abstract][Full Text] [Related]
24. Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes.
Liao HY; Wang SC; Ko YA; Lin KI; Ma C; Cheng TR; Wong CH
Proc Natl Acad Sci U S A; 2020 Jul; 117(30):17757-17763. PubMed ID: 32669430
[TBL] [Abstract][Full Text] [Related]
25. Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques.
Jegaskanda S; Amarasena TH; Laurie KL; Tan HX; Butler J; Parsons MS; Alcantara S; Petravic J; Davenport MP; Hurt AC; Reading PC; Kent SJ
J Virol; 2013 Dec; 87(24):13706-18. PubMed ID: 24109221
[TBL] [Abstract][Full Text] [Related]
26. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
[TBL] [Abstract][Full Text] [Related]
27. Induction of H7N9-Cross-Reactive Antibody-Dependent Cellular Cytotoxicity Antibodies by Human Seasonal Influenza A Viruses that are Directed Toward the Nucleoprotein.
Jegaskanda S; Co MDT; Cruz J; Subbarao K; Ennis FA; Terajima M
J Infect Dis; 2017 Mar; 215(5):818-823. PubMed ID: 28011910
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Administration of Broadly Neutralizing FI6 Antibody Reveals Lack of Interaction Between Human IgG1 and Pig Fc Receptors.
Morgan SB; Holzer B; Hemmink JD; Salguero FJ; Schwartz JC; Agatic G; Cameroni E; Guarino B; Porter E; Rijal P; Townsend A; Charleston B; Corti D; Tchilian E
Front Immunol; 2018; 9():865. PubMed ID: 29740451
[TBL] [Abstract][Full Text] [Related]
29. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies.
Jegaskanda S; Job ER; Kramski M; Laurie K; Isitman G; de Rose R; Winnall WR; Stratov I; Brooks AG; Reading PC; Kent SJ
J Immunol; 2013 Feb; 190(4):1837-48. PubMed ID: 23319732
[TBL] [Abstract][Full Text] [Related]
30. A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses.
Kongchanagul A; Samnuan K; Wirachwong P; Surichan S; Puthavathana P; Pitisuttithum P; Boonnak K
Vaccine; 2020 Jan; 38(4):852-858. PubMed ID: 31708176
[TBL] [Abstract][Full Text] [Related]
31. Stalking influenza by vaccination with pre-fusion headless HA mini-stem.
Valkenburg SA; Mallajosyula VV; Li OT; Chin AW; Carnell G; Temperton N; Varadarajan R; Poon LL
Sci Rep; 2016 Mar; 6():22666. PubMed ID: 26947245
[TBL] [Abstract][Full Text] [Related]
32. Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.
Klausberger M; Tscheliessnig R; Neff S; Nachbagauer R; Wohlbold TJ; Wilde M; Palmberger D; Krammer F; Jungbauer A; Grabherr R
PLoS One; 2016; 11(4):e0153579. PubMed ID: 27088239
[TBL] [Abstract][Full Text] [Related]
33. Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice.
He F; Prabakaran M; Rajesh Kumar S; Tan Y; Kwang J
Antiviral Res; 2014 May; 105():143-51. PubMed ID: 24637255
[TBL] [Abstract][Full Text] [Related]
34. Prime-Boost Vaccination With a Novel Hemagglutinin Protein Produced in Bacteria Induces Neutralizing Antibody Responses Against H5-Subtype Influenza Viruses in Commercial Chickens.
Sączyńska V; Romanik-Chruścielewska A; Florys K; Cecuda-Adamczewska V; Łukasiewicz N; Sokołowska I; Kęsik-Brodacka M; Płucienniczak G
Front Immunol; 2019; 10():2006. PubMed ID: 31552018
[TBL] [Abstract][Full Text] [Related]
35. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA.
Bangaru S; Zhang H; Gilchuk IM; Voss TG; Irving RP; Gilchuk P; Matta P; Zhu X; Lang S; Nieusma T; Richt JA; Albrecht RA; Vanderven HA; Bombardi R; Kent SJ; Ward AB; Wilson IA; Crowe JE
Nat Commun; 2018 Jul; 9(1):2669. PubMed ID: 29991715
[TBL] [Abstract][Full Text] [Related]
36. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119
[TBL] [Abstract][Full Text] [Related]
37. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses.
Jegaskanda S; Vandenberg K; Laurie KL; Loh L; Kramski M; Winnall WR; Kedzierska K; Rockman S; Kent SJ
J Infect Dis; 2014 Dec; 210(11):1811-22. PubMed ID: 24916185
[TBL] [Abstract][Full Text] [Related]
38. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies.
Sui J; Sheehan J; Hwang WC; Bankston LA; Burchett SK; Huang CY; Liddington RC; Beigel JH; Marasco WA
Clin Infect Dis; 2011 Apr; 52(8):1003-9. PubMed ID: 21460314
[TBL] [Abstract][Full Text] [Related]
39. Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies.
Nakajima R; Supnet M; Jasinskas A; Jain A; Taghavian O; Obiero J; Milton DK; Chen WH; Grantham M; Webby R; Krammer F; Carter D; Felgner PL; Davies DH
mSphere; 2018 Dec; 3(6):. PubMed ID: 30541779
[TBL] [Abstract][Full Text] [Related]
40. Generation of a protective murine monoclonal antibody against the stem of influenza hemagglutinins from group 1 viruses and identification of resistance mutations against it.
Wang W; Vassell R; Song HS; Chen Q; Keller PW; Verma S; Alvarado-Facundo E; Wan H; Schmeisser F; Meseda CA; Weir JP; Weiss CD
PLoS One; 2019; 14(9):e0222436. PubMed ID: 31513662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
